IL17A and neoplasm: The KEGG analysis of core targets indicated that BZYQ affects multiple signaling pathways related to tumor and inflammation in the treatment of CRF, including TNF, IL-17, Toll-like receptor (TLR), NF-κB, and C-type lectin receptor (CLR) signaling pathways.